ECCO: MRI screening for women with a family history of breast cancer

MRI screening for women with a family history of breast cancer

 MRI screening for women with a family history of breast cancer but no genetic predisposition is expensive but could be cost-effective for some

abstract: Screening Mammography Use among Current, Former, and Never Hormone Therapy Users May Not Explain Recent Declines in Breast Cancer Incidence

Conclusions:
Differential screening mammography rates by HT use do not explain invasive breast cancer incidence declines. Our data suggest discontinuing HT has an immediate effect on breast cancer rates, lending support to the mechanism that cessation leads to tumor regression.

Impact:
Studies examining the influence of a changing exposure in relation to outcomes should account for varying exposures, individuals' characteristics, as well as screening methods and frequency.

Correspondence/s: Breast-Cancer Screening — NEJM

Epigenomics Initiates PMA Submission for Colorectal Cancer Test | GenomeWeb Daily News | MDx | GenomeWeb

For its clinical module, Epigenomics will need to demonstrate that Epi proColon performs at least as well as fecal immunochemical testing, it said, adding that it has been in discussions with FDA about the design for its clinical study, which it expects to initiate in the coming months after the study's protocol has been finalized.

The clinical module for the PMA submission will include results of the head-to-head comparison with fecal immunochemical testing, previously announced data from a clinical validation study in a cohort of prospectively collected samples, and other clinical study results.

Last month, the Berlin, Germany-based molecular diagnostics firm announced clinical validation study results for the test. The test demonstrated 68 percent sensitivity and 80 percent specificity.

The Canadian Press: More testing coming for Ontario women at risk of contracting breast cancer

Breast Cancers Between Mammograms Rise as Threat - NYTimes.com (research Ontario Breast Cancer Screening Program)

"....Scientists know that both missed tumors and interval cancers tend to be larger and more advanced than tumors detected at regular screenings. Now a new study reports that interval cancers are more aggressive than missed tumors......